Janux Therapeutics, Inc. Gross margin
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
| Gross margin | 0.0% | 0.0% | 96.9% | 90.2% | 75.8% | 100.0% |
Janux Therapeutics, Inc. (JANX) Gross margin comparison analysis
General
LTM Gross margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
JANX key stats
| Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 3.6 0.0% | 8.6 136.8% | 8.1 (6.1%) | 10.6 31.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.8 | 2.0 | 0.0 |
% margin | (0.0) 0.0% | (0.0) 0.0% | 3.5 96.9% | 7.8 90.2% | 6.1 75.8% | 10.6 100.0% |
| Operating Expenses | 3.8 | 4.8 | 36.6 | 75.7 | 81.1 | 109.4 |
| Research & Development Expenses (R&D) | 3.0 | 3.0 | 26.2 | 53.4 | 54.9 | 68.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.8 | 1.8 | 10.3 | 22.3 | 26.1 | 41.0 |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.9) (905.4%) | (67.1) (779.0%) | (73.0) (902.9%) | (98.8) (933.6%) |
| Interest Income | 0.2 | 0.2 | 0.3 | 4.0 | 14.7 | 29.9 |
| Interest Expense | 0.2 | 0.2 | 0.0 | 4.0 | 0.0 | 0.0 |
| Pre-tax Income | (4.0) | (6.8) | (32.7) | (63.1) | (58.3) | (69.0) |
% effective tax rate | 0.2 (5.8%) | (1.5) 22.5% | (0.1) 0.3% | (8.9) 14.1% | 0.0 0.0% | 0.0 0.0% |
% margin | (4.2) 0.0% | (5.3) 0.0% | (32.6) (895.2%) | (54.2) (628.8%) | (58.3) (721.2%) | (69.0) (651.6%) |
| EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
| Diluted EPS | (0.10) | (0.13) | (0.79) | (1.31) | (1.32) | (1.28) |
% margin | (3.8) 0.0% | (4.8) 0.0% | (32.8) (902.3%) | (66.3) (769.3%) | (71.0) (878.7%) | (98.8) (933.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Janux Therapeutics, Inc.'s Gross margin?
As of today, Microsoft Corp's last 12-month Gross margin is 90.2%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Gross margin for Janux Therapeutics, Inc. have been (82.5%) over the past three years, and (115.0%) over the past five years.
2) Is Janux Therapeutics, Inc.'s Gross margin Good?
As of today, Janux Therapeutics, Inc.'s Gross margin is 90.2%, which is higher than industry median of 69.2%. It indicates that Janux Therapeutics, Inc.'s Gross margin is Good.